Mira Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: MIRA · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Mira Pharma filed an 8-K for a shareholder vote. Keep an eye on what they're voting on.
AI Summary
Mira Pharmaceuticals, Inc. filed an 8-K on September 12, 2024, to report on a submission of matters to a vote of security holders. The company, formerly known as Mira1a Therapeutics, Inc., is incorporated in Florida and has its principal executive offices in Miami.
Why It Matters
This filing indicates that Mira Pharmaceuticals is engaging in a process that requires shareholder approval, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote matter, not an event that inherently signals significant financial risk.
Key Players & Entities
- MIRA PHARMACEUTICALS, INC. (company) — Registrant
- Mira1a Therapeutics, Inc. (company) — Former company name
- September 12, 2024 (date) — Date of report
- Florida (location) — State of incorporation
- Miami (location) — Principal executive office city
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that a submission of such matters is being reported.
When was the company formerly known as Mira1a Therapeutics, Inc.?
The company's name change from Mira1a Therapeutics, Inc. to Mira Pharmaceuticals, Inc. occurred on January 12, 2022.
What is the principal executive office address of Mira Pharmaceuticals, Inc.?
The principal executive offices are located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
What is the company's telephone number?
The registrant's telephone number is (737) 289-0835.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 736 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2024-09-12 16:30:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 59KB
- 0001493152-24-036057.txt ( ) — 234KB
- mira-20240912.xsd (EX-101.SCH) — 3KB
- mira-20240912_lab.xml (EX-101.LAB) — 33KB
- mira-20240912_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: September 12, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer